Clinical trial · Interventional
Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma
NCT00286013CI-TRIAL-00062607completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate the feasibility defined as overall tolerance and toxicity as well as relative dose-intensity and cumulative dose delivered, of an association ofgemcitabine, oxaliplatin and radiotherapy in patients with locally advanced and unresectable, but non-metastatic pancreatic adenocarcinoma or cholangiocarcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced and Unresectable, But Non-metastatic Pancreatic Adenocarcinoma or Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Association of gemcitabine, oxaliplatin and radiotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Feasibility
- measure
- Tolerance
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven and unresectable adenocarcinoma of the pancreas or cholangiocarcinoma with no evidence of metastatic disease * WHO performance status of 0 or 1 * Complete recovrey from surgery in case an enteric and/or biliary tract by-pass operation has been performed * Maximum delay after surgery: 8 weeks * No previous or co-existent malignant disease except non melanoma skin cancers and adequately treated cervic carcinoma in situ * Adequate bon marrow reserve * No previous chemotherapy or radiotherapy * Expected survival \> 6 months Exclusion Criteria: * Active infection * Metastatic disease * Inadequate liver function after derivative surgery * Inadequate renal function * Pregnancy, breast feeding * Use of any other investigational agent in the month before enrollment * Patients with grade 2 or more neuropathy
References
Publications (0)
Data not yet available
No reference posted for this study.